

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P50955RC3	Predecessor SERIAL NO. 10/323,101 10/758,506
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Bast, et al.	
(Use several sheets if necessary)		FILING DATE herewith	GROUP 16/4

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
LAR	US 6,001,631	12/14/99	Blanche et al.	435	233	1/24/97

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
LAR	WO 00/24932	5/4/00	PCT				
LAR	WO 96/03516	2/8/96	PCT				


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LAR	Andriole, V.T., The Future of the Quinolones, Drugs, Vol 58, Suppl 2, 1-5 (1999)
LAR	Baranova et al., Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of streptococcus pneumoniae, Antimicrobial Agents and Chemotherapy, June 1997, 1396-1398
LAR	Breiman, et al., Emergence of Drug-Resistant Pneumococcal Infections in the United States, JAMA, June 15, 1994, Vol 271, No. 23, 1831-1835
LAR	Brenwald et al., The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of streptococcus pneumoniae to norfloxacin, J. Antimicrob Chemother 1997, 40, 458-460
LAR	Brenwald, et al, Prevalence of a Putative Efflux mechanism among Fluoroquinolone-Resistant. Clinical Isolates of Streptococcus pneumoniae, Antimicrobial Agents and Chemotherapy, 42(8): 2032-2035 (1998)
LAR	Brenwald, et al., Grepafloxacin vs Pneumococci Resistant to Fluoroquinolones by a Putative Efflux Mechanism, Drugs, Vol 58, Suppl 2, 117-118 (1999)
LAR	Bryskier, A., Update, Anti-infectives, Novelties in the field of fluoroquinolones, Exp. Opin. Invest. Drugs (1997) 6(9):1227-1245
LAR	Chen, D.K., et al., Decreased Susceptibility of Streptococcus Pneumoniae to Fluoroquinolones in Canada, New England Jnl of Medicine, Vol 341, No. 4, 233-239 (July 22, 1999)
LAR	Chu, D.T.W., The Future Role of Quinolones, Exp. Opin. Ther. Patents (1996) 6(8) 711-737
LAR	Davies, et al., In vitro Development of Resistance to Five Quinolones and Amoxicillin-Clavulanate in Streptococcus pneumoniae, Antimicrobial Agents and Chemotherapy, 43(5): 1177-1182 (1999)

[Handwritten Signature]


2 June 2005

LAR	Discotto, L.F., et al., 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 24-27, 1998, San Diego, CA, USA, Exp. Opin. Invest. Drugs (1998) 7(12) 2061-2977
	Drugline, Molecule of the Month, Drug News Perspect 11(8), October 1998, 505
	Erwin, M.E., et al., Studies to Establish Quality Control Ranges for SB-265805 (LB20304) When Using National Committee for Clinical Laboratory Standards Antimicrobial Susceptibility Test Methods, Journal of Clinical Microbiology, Jan. 1999, 279-280
	Friedland, et al., Management of Infections Caused by Antibiotic-Resistant Streptococcus pneumoniae, New England Journal of Medicine, 331(6): 377-382 (1994)
	Garau, J., The Role of Quinolones in the Treatment of Community-Acquired Pneumonia, Medicina Clinica, Vol 110, Suppl 1, 31-35 (Feb 1998), and English language abstract
	Georgiou, et al., Ciprofloxacin-Resistant Haemophilus influenzae Strains Process Mutations in Analogous Positions of GyrA and ParC, Antimicrobial Agents and Chemotherapy, 40(7): 1741-1744, (1996)
	Gill et al., Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in streptococcus pneumoniae, Antimicrobial Agents and Chemotherapy, Jan. 1999, 187-189
	Gonzalez et al., Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci, Antimicrobial Agents and Chemotherapy, Nov. 1998, 2792-2798
	Graul, A., et al., SB-265805/LB-20304a Naphthyridine Antibacterial, Drugs Future, Vol 23(11) 1199-1204 (1998)
	Hooper, Mode of Action of Fluoroquinolones, Drugs, Vol 58, Suppl 2, 6-10 (1999)
	Jacobs, Treatment and Diagnosis of Infections Caused by Drug-Resistant Streptococcus pneumoniae, Clinical Infectious Diseases, 15: 119-127 (1992)
	Jacobs, et al., Antibiotic-resistant pneumococci, Review in Medical Microbiology, 6(2): 77-93 (1995)
	Jacobs, et al., Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 Oral Antimicrobial Agents Based on Pharmacodynamic Parameters: 1997 U.S. Surveillance Study, Antimicrobial Agents and Chemotherapy, 43(8): 1901-1908 (1999)
	Janoir et al, High-level fluoroquinolone resistance in streptococcus pneumoniae requires mutations in parC and gyr A, Antimicrobial Agents and Chemotherapy, Dec 1996, 2760-2764
	Johnson, D.M., et al., Anti-Streptococcal Activity of SB-265805 (LB20304), a Novel Fluoronaphthyridone, Compared With Five Other Compounds, Including Quality Control Guidelines, Diagn Microbiol Infect Dis 1999; 33:87-91
	Journal of Antimicrobial Chemotherapy, 21st International Congress of Chemotherapy, Birmingham UK, July 4-7, 1999, Suppl. A to Vol. 44 July 1999, pp. 125-127, 130-132, 135-136, 139-142, 144-148; 21st ICC poster nos. P 385, 386, 391, 406, 408, 413, 429, 434, 449, 452, 454, 460-462, 474, 477, 482, 484, 486-488, 491, 492
	McDougal, et al., Analysis of Multiply Antimicrobial-Resistant Isolates of Streptococcus pneumoniae, Antimicrobial Agents and Chemotherapy, 36(10): 2176-2184 (1992)
LAR	Munoz et al, ParC subunit of DNA topoisomerase IV of streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype, Antimicrobial Agents and Chemotherapy, Oct 1996, 2252-2257

 2 June 2005

10/758,506

LAR	Licata, et al., Comparison of the Postantibiotic and Postantibiotic Sub-MIC Effects of Levofloxacin and Ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae, Antimicrobial Agents and Chemotherapy, 41(5): 950-955 (1997)
	Pan, et al., Involvement of Topoisomerase IV and DNA Gyrase as Ciprofloxacin Targets in Streptococcus pneumoniae, Antimicrobial Agents and Chemotherapy, 40(10): 2321-2326 (1996)
	Pan et al., Targeting of DNA gyrase in streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones, Antimicrobial Agents and Chemotherapy, Feb. 1997, 471-474
	Pan et al., DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in streptococcus pneumoniae, Antimicrobial Agents and Chemotherapy, Nov. 1998, 2810-2816
	Pankuch, et al., Study of Comparative Antipneumococcal Activities of Penicillin G, RP 59500, Erythromycin, Sparfloxacin, Ciprofloxacin, and Vancomycin by Using Time-Kill Methodology, Antimicrobial Agents and Chemotherapy, 38(9): 2065-2072(1994)
	Pankuch, et al., Activity of CP99.219 compared with Du-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and gatifloxacin against penicillin-susceptible and-resistant pneumococci, Journal of Antimicrobial Chemotherapy, 35: 230-232 (1995)
	Pankuch, et al., Antipneumococcal Activities of RP59500 (Quinupristin-Dalfopristin) Penicillin G, Erythromycin, and Sparfloxacin Determined by MIC and Rapid Time-Kill Methodologies, Antimicrobial Agents and Chemotherapy, 40(7): 1653-1656 (1996)
	Perichon et al., Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in streptococcus pneumoniae, Antimicrobial Agents and Chemotherapy, May 1997, 1166-1167
	Piddock et al., Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract, Antimicrobial Agents and Chemotherapy, Nov. 1998, 2956-2960
	Piddock, Mechanisms of Fluoroquinolone Resistance: An Update 1994-1998, Drugs, Vol 58, Suppl 2, 11-18 (1999)
	Reinert, R.R., et al., In Vitro Activity of SB-265805 Against Streptococcus pneumoniae in Germany, Clin. Microbiol. and Infection, 1999, Vol. 5, Suppl. 3, 143, Abstract P219, and poster P219 (ECCMID March 1999, Germany)
	Smirnov, A. et al., Gemifloxacin is Effective in Experimental Pneumococcal Meningitis, Clin. Microbiol. and Infection, 1999, Vol. 5, Suppl. 3, 144, Abstract P223, and poster P223 (ECCMID March 1999, Germany)
	Spangler, et al., Susceptibilities of Penicillin-Susceptible and -Resistant Strains of Streptococcus pneumoniae to RP59500, Vancomycin, Erythromycin, PD 131628, Sparfloxacin, Temafloxacin, Win 57272, Ofloxacin, and Ciprofloxacin, Antimicrobial Agents and Chemotherapy, 36(4): 856-859 (1992)
	Spangler, et al., Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829, Journal of Antimicrobial Chemotherapy, 31: 273-280 (1993)
LAR	Spangler, et al., Postantibiotic Effect and Postantibiotic Sub-MI Effect of Levofloxacin Compared to Those of Ofloxacin, Ciprofloxacin, Erythromycin, Azithromycin, and Clarithromycin against 20 Pneumococci, Antimicrobial Agents and Chemotherapy, 42(5): 1253-1255 (1998)

 2 June 2005

10/758,506

LAR	Tankovic et al, Contribution of Mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of streptococcus pneumoniae obtained in vivo and in vitro, Antimicrobial Agents and Chemotherapy, Nov 1996, 2505-2510
	Visalli, et al., MIC and Time-Kill Study of Activities of DU-6859a, Ciprofloxacin, Levofloxacin, Sparfloxacin, Cefotaxime, Imipenem, and Vancomycin against Nine Penicillin-Susceptible and-Resistant Pneumococci, Antimicrobial Agents and Chemotherapy, 40(2): 362-366 (1996)
LAR	Zeller et al., Active efflux as a mechanism of resistance to ciprofloxacin in streptococcus pneumoniae, Antimicrobial Agents and Chemotherapy, Sept. 1997, 1973-1978
EXAMINER	DATE CONSIDERED 27 June 2005
EXAMINER - Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P50955RC3	PREDECESSOR SERIAL NO. 10/323,101 10/758,506
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Bast, et al.	
		FILING DATE Herewith	GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
LAR	5,633,262	5/27/97	Hong et al.			
	5,776,944	7/7/98	Hong et al.			
	5,869,670	2/9/99	Hong et al.			
LAR	5,962,468	10/5/99	Hong et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes	No
LAR	WO 98/42705	01.10.98	PCT				
LAR	EP 688772 A1	27.12.95	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LAR	G. Cormican, "Comparative Antimicrobial and Spectrum Activity of LB20304a, a New Fluoronated Naphthyridone Compound", <u>Abstracts of the 36th ICAAC</u> , 109 Abst F53 (1996)
	J-H. Kwak, "Antimicrobial Activities of LB20304a, a New Quinolone Antibiotic", <u>The Journal of Applied Pharmacology</u> (4) pp. 378-384 (1996)
	M-K. Seo, "Pharmacokinetics of LB20304, a New Fluoroquinolone, in Rats and Dogs", <u>Arch. Pharm. Res.</u> Vol. 19, No. 5, pp. 359-367 (1996)
	C. Yong Hong, et al., "Novel Fluoroquinolone Antibacterial Agents Containing Oxime-Substituted (Aminomethyl) pyrrolidines: Synthesis and Antibacterial Activity of 7-(4-(Aminomethyl)-3-(methoxyimino) pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro [1,8] naphthyridine-3-carboxylic Acid (LB20304)", <u>J. Med. Chem.</u> 40 (22) pp. 3584-3593 (1997)
	M-K. Seo et al., "High Performance Liquid Chromatographic Assay of a New Fluoroquinolone, LB20304, in the Plasma of Rats and Dogs", <u>Arch. Pharm. Res.</u> Vol. 19, No. 6, pp. 554-558 (1996)
	M-J. Ahn, et al., "InVivo Efficacy of LB20304a against Experimental Respiratory Tract Infection in Mice", <u>Yakhak Hoeji</u> Vol. 40, No. 4, pp. 438-441 (1996)
	M-J. Ahn, et al., "Effect of a New Fluoroquinolone LB20304a on Microflora of Caecum in Mice", <u>Yakhak Hoeji</u> Vol 40, No. 3, pp. 343-346 (1996)
	K-S. Paek, et al., "Factors Affecting In Vitro Activity of LB20304, New Fluoroquinolone", <u>Arch. Pharm. Res.</u> Vol. 19, No. 2, pp. 143-147 (1996)
	M-J. Ahn, et al, "Post-Antibiotic Effect of LB20304, A New Quinolone Antibiotic", <u>Yakhak Hoeji</u> Vol. 40, No. 3, pp. 347-350 (1996)
	F. Marco, et al., "Antimicrobial Activity of LB20304, a Fluoronaphthyridone, Tested Against Anaerobic Bacteria", <u>J. Antimicrobial Chemother</u> Vol. 40, No. 4, pp. 605-607 (1997)
	M. G. Cormican, et al, "Antimicrobial Activity and Spectrum of LB20304, a Novel Fluoronaphthyridone", <u>Antimicrobial Agents. Chemotherapy</u> Vol. 41, No. 1, pp. 204-211 (1997)
LAR	A. F. Hohl, et al, "International Multicenter Investigation of LB20304, a New Fluoronaphthyridone", <u>Clin. Microbiol. Infect.</u> Vol. 4, No. 5, pp. 280-284 (1998)
	DATE CONSIDERED 2 June 2005

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

[illegible][illegible]